Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-06-06 | Reverse | 1:30 |
IN8bio, Inc. is a clinical-stage biotech developing gamma-delta T cell therapies for cancers, with lead candidates INB-200 and INB-100 in Phase I trials for glioblastoma, solid tumors, and leukemia.

IN8bio is developing INB-100, a gamma-delta T cell therapy for high-risk AML patients undergoing stem cell transplantation, with a focus on advancing this lead candidate as of late 2024.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
BCDA | $1.08 | COMPARE |
PHIO | $1.08 | COMPARE |
KPRX | $2.55 | COMPARE |
APRE | $0.79 | COMPARE |
ACXP | $1.42 | COMPARE |
RNAZ | $2.06 | COMPARE |
APVO | $1.74 | COMPARE |
HCWB | $2.94 | COMPARE |